Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of FZJ-003 in Healthy Volunteers
NCT04715529Phase 1Completed
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD), ulcerative colitis (UC) and rheumatoid arthritis (RA) comparing FZJ-003 with Placebo (2 arms). Primary endpoint: Number of volunteers with adverse events. Started Jan 2021; status: completed.
02
Drugs
fzj-003
03
Conditions
atopic dermatitis (AD)ulcerative colitis (UC)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04715529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04715529.